Related Experiment Video
Updated: May 6, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Protein disulfide isomerase: a promising target for cancer therapy
Shili Xu1, Saranya Sankar2, Nouri Neamati1
1Department of Medicinal Chemistry, College of Pharmacy and Translational Oncology Program, University of Michigan, North Campus Research Complex, 2800 Plymouth Road, Building 520, Ann Arbor, MI 48109, USA.
Abstract:
Protein disulfide isomerase (PDI) has a key role in maintaining cellular homeostasis by mediating oxidative protein folding. It catalyzes disulfide bond formation, breakage and rearrangement in the endoplasmic reticulum and has chaperone protein activity. Increasing evidence suggests that PDI supports the survival and progression of several cancers. During the past decade, robust PDI activity assays have been developed and several PDI inhibitors identified, but none has been approved for clinical use. Herein, we review current knowledge of the role of PDI in cancer and discuss various assays for measuring the activities of PDI, highlighting their sensitivities and usefulness for high-throughput screening. The previously reported PDI inhibitors require further validation to serve as bona fide leads and additional optimization to generate novel drug candidates for clinical studies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Sulfur Assimilation

